Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$-1.37
EPS est.
$-0.95
EPS surprise
-44.51%
1-day move
-3.27%
Viking Therapeutics reported a larger-than-expected loss per share, which contributed to a 3.27% decline in its stock price. The lack of revenue and guidance further adds uncertainty for investors. Overall, the disappointing EPS results may raise concerns about the company's financial health moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.37 | $-0.91 | -44.51% |
| Revenue | N/A | $0M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant as it addresses unmet medical needs in the health care sector, particularly in the treatment of conditions like obesity and diabetes.
Last quarter
In the last quarter, Viking Therapeutics reported an EPS of $-1.38, missing the estimate of $-0.89. The stock reacted negatively, declining by 0.70% the following day.
EPS beat streak
1Q
EPS beat rate
25%
Avg EPS surprise
-21.04%
Avg 1-day reaction
-0.48%
Analysts expect Viking to report a loss this quarter, with a consensus EPS of $-0.91. Given the company's history of missing earnings expectations, there is a cautious sentiment among investors.
Bull case
If Viking can narrow its losses significantly or provide positive updates on its drug pipeline, it could boost investor confidence and lead to a positive stock reaction.
Bear case
Conversely, if the company reports a larger loss than expected or fails to provide any new insights into its future revenue potential, it could lead to further declines in the stock price.
Key metrics to watch
EPS
$-0.91Earnings per share (EPS) is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$0MWhile no revenue is expected this quarter, any updates on future revenue streams could impact investor sentiment.
The print will turn on these.
Q1
Will Viking provide any updates on its drug pipeline that could signal future revenue potential?
Investors are keen to understand how the company plans to generate revenue, especially given the lack of expected revenue this quarter.
Q2
How does Viking plan to address its ongoing losses, and what steps are being taken to improve profitability?
Management's response to profitability concerns will be critical for investor confidence and could influence stock performance.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The Street may be overly pessimistic about Viking's potential for revenue generation, especially if there are positive developments in its drug pipeline that have not been fully accounted for.
Supporting evidence
The options market is pricing in an 8.67% move, indicating expectations of volatility that may not align with the actual performance.
Viking's historical performance shows a tendency to surprise on the upside, even when consensus is cautious.
Key risk
If Viking provides any positive updates on its drug pipeline or plans for future revenue, it could significantly shift market sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around the company's ability to manage its losses and provide a clear path to future profitability.
Bull confirmed if
A narrower loss than the consensus estimate of $-0.91 could confirm a more optimistic outlook.
Bear confirmed if
A larger loss than expected, particularly if it exceeds $-1.43, would reinforce bearish sentiment.
What the market is pricing for the move.
Implied Move
±8.67%
Historical Avg
±2.7%
The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.
Options are pricing ±8.5% while VKTX has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
1.4%
30d HV
53.3%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 11 of 25 (44%)
This setup has occurred 30 times across Health Care in the last 2 years. 11 of 25 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.3%, with a raw directional average of +2.3% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
60.60%
of float
Insider
2.84%
of float
Holders
572
institutions
Top Holders· as of Jun 2026
FMR, LLC
6,335,756 sh · $180.8M
5.03%
5.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Viking beats expectations and narrows its losses, history suggests the stock could rise by an average of 1.54% the next day.
In line / cautious
If results are in line with expectations, management's commentary could lead to a muted response, reflecting cautious sentiment.
Miss
If the company misses expectations, history suggests a potential decline of about 0.67% the following day.
The lines on the call that would change the story.
Blackrock Inc.
6,189,649 sh · $176.7M
4.91%
-10.0%
State Street Corporation
5,606,394 sh · $160.0M
4.45%
27.6%
Vanguard Capital Management LLC
5,053,663 sh · $144.2M
4.01%
0.8%
Vanguard Portfolio Management LLC
4,484,263 sh · $128.0M
3.56%
0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.